Psoriasis Disease Pipeline Drugs Assessment By Trial Phase (Preclinical Trials, Phase 1, Phase 2, Phase 3, Phase 4, By Drugs (Icotinib Hydrochloride, Bimekizumab, Calcipotriene ,Ustekinumab, Risankizumab, Methotrexate, Others) Condition (Plaque psoriasis, Scalp psoriasis, Guttate psoriasis, Nail psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis, Psoriatic arthritis), Route of Administration (Oral, Parenteral) and Region    

Psoriasis is a genetic inflammatory disease that affects the skin. Psoriasis is charecterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, they rise, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the  scalp, elbows, and knees.

Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues,Topical retinoids, Calcineurin inhibitors etc. and it can be treated by phototherapy

Key Developments:

• In November 2016,Janssen-Cilag submitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis
• In March 2016, Dr. Reddy's Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddys Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPorts clinical-stage oral new chemical entity, XP23829. Dr. Reddys Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis